Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies

Carlos Agustin Villegas-Valverde; Antonio Alfonso Bencomo-Hernandez; Yandy M Castillo-Aleman; Yendry Ventura-Carmenate; Imilla Casado-Hernandez; Rene Antonio Rivero-Jimenez

doi:10.1016/j.htct.2023.10.008

Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies

Hematol Transfus Cell Ther. 2023 Dec 29:S2531-1379(23)02600-7. doi: 10.1016/j.htct.2023.10.008. Online ahead of print.

Authors

Carlos Agustin Villegas-Valverde¹, Antonio Alfonso Bencomo-Hernandez², Yandy M Castillo-Aleman², Yendry Ventura-Carmenate², Imilla Casado-Hernandez², Rene Antonio Rivero-Jimenez²

Affiliations

¹ Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab Emirates. Electronic address: carlos.villegas@adscc.ae.
² Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab Emirates.

PMID: 38177056
DOI: 10.1016/j.htct.2023.10.008

Abstract

Introduction: Hematopoietic stem cell transplantation (HSCT) is a widely used therapy, but its success largely depends on the number and quality of stem cells collected. Current evidence shows the complexity of the hematopoietic system, which implies that, in the quality assurance of the apheresis product, the hematopoietic stem cells are adequately characterized and quantified, in which mass cytometry (MC) can provide its advantages in high-dimensional analysis.

Objective: This research aimed to characterize and enumerate CD45^dim/CD34⁺ stem cells using the MC in apheresis product yields from patients with chronic lymphoid malignant diseases undergoing autologous transplantation at the Abu Dhabi Stem Cells Center.

Methods: An analytical and cross-sectional study was performed on 31 apheresis products from 15 patients diagnosed with multiple myeloma (n = 9) and non-Hodgkin lymphomas (n = 6) eligible for HSCT. The MC was employed using the MaxPar Kit for stem cell immunophenotyping. The analysis was performed manually in the Kaluza and unsupervised by machine learning in Cytobank Premium.

Results: An excellent agreement was found between mass and flow cytometry for the relative and absolute counts of CD45^dim/CD34⁺ cells (Bland-Altman bias: -0.029 and -64, respectively), seven subpopulations were phenotyped and no lineage bias was detected for any of the methods used in the pool of collected cells. A CD34+/CD38+/CD138+ population was seen in the analyses performed on four patients with multiple myeloma.

Conclusions: The MC helps to characterize subpopulations of stem cells in apheresis products. It also allows cell quantification by double platform. Unsupervised analysis allows results completion and validation of the manual strategy. The proposed methodology can be extended to apheresis products for purposes other than HSCT.

Keywords: Apheresis; Autologous hematopoietic stem cell transplant (AHSCT); Flow and mass cytometry; Hematological malignancies; Immunophenotyping.